DOCSLIB.ORG

Acute Liver Problems

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Acute Liver Problems Acute Liver Problems Dr. Martin James PhD FRCP Nottingham University Hospitals HST GIM Teaching December 2016 Priorities for liver disorders? • What will I see on the acute take? • Which patients need urgent management? • What are the priorities for treatment? • What’s new in liver disease? Clinical Priorities • Decompensated chronic liver disease - 80% – Variceal haemorrhage – Ascites & infection – Encephalopathy – Hepatorenal syndrome • Acute liver failure - <5% • Biliary sepsis - 15% BACKGROUND Lifestyle & liver disease? Alcohol NAFLD Viral Hepatitis Hepatitis C virus (HCV) Annual diagnosis SVR (cure) in 2016 1700 440 Annual Treatment 16,000 460 250 Annual Incidence 900 Cure 2012 Adapted from HPA/Roche 2012 New HCV therapies Accessing HCV therapy? Alcohol consumption Caner Research UK 2010 Death between 35-59 years from cirrhosis and other selected diseases: UK 1952-2009 30 Men 30 Women 25 25 20 20 Coronary heart disease 15 15 Lung 10 cancer 10 Deaths Deaths per 10 000 man-years Coronary Deaths Deaths per 10 000 woman-years heart Stroke disease Breast 5 5 cancer Stroke Cirrhosis Cirrhosis 0 0 1950 1960 1970 1980 1990 2000 2010 1950 1960 1970 1980 1990 2000 2010 Year Year Bhala, Foster & Aithal. BMJ 2013 Silly Money? Prevention Cure Preventing liver deaths? NHS Atlas of Liver disease 2013 WHICH PATIENTS NEED URGENT MANAGEMENT? In-patient jaundice Biliary obstruction Alcohol-related liver disease Other liver diseases, drugs, infection, cancers Clinical Priorities • Decompensated chronic liver disease – Variceal haemorrhage – Ascites & infection – Encephalopathy – Hepatorenal syndrome • Acute liver failure • Biliary sepsis Decompensated Cirrhosis • Jaundice • Bleeding Cirrhosis • Ascites “bundle” & consider assessment for • Encephalopathy transplantation • Hepatorenal syndrome Cause of decompensation? • Sepsis • Also consider: – Ascites – Head injury – biliary – Drug ingestion/ toxicity – chest – diuretics – UTI – Electrolytes disturbance – CNS – Hypoglycaemia – skin – Constipation • GI Bleeding – dehydration • Progression of CLD – HCC development DKA, MI etc – PV thrombosis – The golden 24 hours • Implementation of the BSG/BASL Decompensated Cirrhosis Care Bundle in acute medicine: • NUH local experience feedback • P.Thiagarajan, C.Peal, D.Gunn, M.James • October 2015 Chronic Liver Disease by Aetiology Baseline Audit: Post-intervention Audit: June 2015 September 2015 3% 3% 4% 4% 7% 7% Alcohol Excess Alcohol Excess, n (%) NAFLD NAFLD, n (%) 14% Viral Hepatitis 17% Viral Hepatitis, n (%) 69% Autoimmune Autoimmune 72% Unknown Unknown Cause for decompensation Sepsis, n (%) 23% Upper GI bleeding, n (%) Dehydration, n (%) 0% 3% 47% Baseline (n=30) Drugs, n (%) 7% Hepatocellular carcinoma, n (%) 20% Unknown, n (%) Sepsis, n (%) 24% Upper GI bleeding, n (%) Post-intervention (n=29) 41% Dehydration, n (%) 3% Drugs, n (%) 4% 4% Hepatocellular carcinoma, n (%) Unknown, n (%) 24% Septic Screen Parameters 100.0 P=0.02 90.0 80.0 P=0.002 70.0 60.0 50.0 Percentage 40.0 30.0 20.0 +39% +15% +22% +65% 10.0 0.0 Blood cultures Urine Dipstick CXR Ascitic tap Baseline 26.7 53.3 53.3 23.5 Post-intervention 65.5 68.9 75.9 88.2 Suspected Variceal Haemorrhage 120.0 P=0.03 P=0.03 100.0 80.0 60.0 Percentage +13% +16% +26% +21% 40.0 +33% 20.0 0.0 Terlipressin Antibiotics Fluid resuscitation Restrictive Transfusion Lactulose Baseline 66.7 60.0 66.7 60.0 68.0 Post-intervention 80.0 85.7 100.0 85.7 89.3 Bleeding & liver disease • Resuscitation • Vasopressors and antibiotics • Correct coagulation (Platelets <50, INR>1.5, Fibrinogen <1.0) – biliary obstruction vs liver failure • Identify source of bleeding • Endoscopic therapy GI bleeding, antibiotics & mortality Soares-Weiser Cochrane Review 2002 Model for Endstage Liver Disease MELD: Bilirubin, PT (INR) and creatinine Gut 2007 TIPS for varices Hepatic vein coils TIPS Portal vein Early (≤72 hours) TIPS Garcia-Pagan et al NEJM 2010 SX-Ella Danis Stent Wright G et al Gastrointestinal Endoscopy 2010 Danis Stent Oesophagus post stent removal Secondary prophylaxis – oesophageal varices Sharara et al NEJM 2001 Diagnostic ascitic tap • Sterile • Anterior axillary line • 50mm cephalic from anterior superior iliac spine • Samples for: WCC MC&S (SAAG, cytology) Serum-ascitic albumin gradient (SAAG) • SAAG serum minus ascitic albumin • High SAAG >11g/L – LR+ for portal hypertension 4.6 (1.6-12.9) – LR- for portal hypertension 0.06 (0.02-0.2) Wong JAMA 2008 Gines NEJM 2006 Spontaneous bacterial peritonitis (SBP) • Increased bacterial translocation in cirrhosis – Usually gut organisms • High ascitic neutrophils/ WCC (even without organism identified) • Sample ascitic fluid aseptically – Neutrophils >250/mm 3, Total WCC>500/mm 3 – Culture fluid in blood culture bottles. GI bleed PPI? lung urine ascites TNF ααα LN IL-1 IL-6, IL-8 vasodilatation endotoxin nitric oxide Reduced renal perfusion Hepatorenal syndrome Resistance C. difficile death Cefotaxime vs Cefotaxime & HAS Sort et al NEJM 1999 Outcome Cefotaxime Cefotaxime & 20% p value albumin Infection resolution 94% 98% 0.36 Urea (day 6) 12.8 7.8 0.03 Creatinine (day 6) 114.9 88.4 0.03 Sodium (day 6) 130 134 <0.001 MAP (mmHg) 79 80 0.71 Renal failure 33% 10% 0.002 Mortality In hospital 29% 10% 0.01 3 months 41% 22% 0.03 Clinical Priorities • Decompensated chronic liver disease – Variceal haemorrhage – Ascites & infection – Encephalopathy – Hepatorenal syndrome • Acute liver failure • Biliary sepsis Acute liver failure (ALF) • Potentially reversible consequence of severe liver injury • Encephalopathy within weeks of the onset of first symptoms • Absence of pre-existing liver disease Causes of acute liver failure • Paracetamol 50% • Hepatitis B 10% • Hepatitis A/E 5% • Other drugs 10% • Cryptogenic (non-A, non-B) 20% Drugs associated with liver injury • Paracetamol • Amoxycillin-clavulinic acid • Flucloxacillin • Nitrofurantoin • Statins • Isoniazid • Propythiouricil Other causes of ALF • Vascular liver diseases – Budd Chiari syndrome – Ischaemic liver injury • Malignant infiltration • Autoimmune hepatitis • Acute fatty liver of pregnancy • Wilson’s disease Clinical case ALT Clinical case - ALT Bili PT Albumin Outcome Prediction - KCH criteria Paracetamol pH <7.3 (alone) Or all 3 of: Grade III to IV encephalopathy PT>100 seconds Creatinine >300 µmol/L (lactate >3.0 mmol/L after resuscitation) Non-paracetamol PT>100 seconds Or any 3 of: Age <10 or >40 years Bad aetiology (NANB, Drugs) Jaundice to encephalopathy >7 days PT > 50s Bilirubin > 300 µmol/L Take home messages - ALF • Sick patients; may deteriorate rapidly • Resuscitate, assess patient and numbers • Transfer to AICU/ liver unit – encephalopathy, rising INR, hypotension or ARF, sepsis, hypoglycaemia or bleeding • Suspicion of paracetamol; use NAC Transplant indications Gut 2011Gut 2007 Transplant; 5-year survival Gut 2007 Clinical Priorities • Decompensated chronic liver disease – Variceal haemorrhage – Ascites & infection – Encephalopathy – Hepatorenal syndrome • Acute liver failure • Biliary sepsis Biliary obstruction Management; ascending cholangitis • Resuscitation and renal support • Check & correct coagulation • Biliary drainage • Antibiotics (e.g. iv tazoxin, cefuroxime) – Organisms: E. Coli, Klebsiella, Streptococcus • Analgaesia Relieve obstruction Malignant obstruction Liver abscess Biliary MDT Summary • Decompensated liver disease increasing – prevention critical – treat complications & consider transplantation • Acute Liver Failure – rare, but early recognition critical • Biliary sepsis – clinical history, imaging, treat sepsis and achieve drainage – MDT approach QUESTIONS?.
Load more

Recommended publications
  • Evaluation of Abnormal Liver Chemistries
    ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries Paul Y. Kwo, MD, FACG, FAASLD1, Stanley M. Cohen, MD, FACG, FAASLD2, and Joseph K. Lim, MD, FACG, FAASLD3 1Division of Gastroenterology/Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA; 2Digestive Health Institute, University Hospitals Cleveland Medical Center and Division of Gastroenterology and Liver Disease, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA; 3Yale Viral Hepatitis Program, Yale University School of Medicine, New Haven, Connecticut, USA. Am J Gastroenterol 2017; 112:18–35; doi:10.1038/ajg.2016.517; published online 20 December 2016 Abstract Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests should be termed liver chemistries or liver tests. Hepatocellular injury is defined as disproportionate elevation of AST and ALT levels compared with alkaline phosphatase levels. Cholestatic injury is defined as disproportionate elevation of alkaline phosphatase level as compared with AST and ALT levels. The majority of bilirubin circulates as unconjugated bilirubin and an elevated conjugated bilirubin implies hepatocellular disease or cholestasis. Multiple studies have demonstrated that the presence of an elevated ALT has been associated with increased liver-related mortality. A true healthy normal ALT level ranges from 29 to 33 IU/l for males, 19 to 25 IU/l for females and levels above this should be assessed. The degree of elevation of ALT and or AST in the clinical setting helps guide the evaluation.
    [Show full text]
  • Choledochoduodenal Fistula Complicatingchronic
    Gut: first published as 10.1136/gut.10.2.146 on 1 February 1969. Downloaded from Gut, 1969, 10, 146-149 Choledochoduodenal fistula complicating chronic duodenal ulcer in Nigerians E. A. LEWIS AND S. P. BOHRER From the Departments ofMedicine and Radiology, University ofIbadan, Nigeria Peptic ulceration was thought to be rare in Nigerians SOCIAL CLASS All the patients were in the lower until the 1930s when Aitken (1933) and Rose (1935) socio-economic class. This fact may only reflect the reported on this condition. Chronic duodenal ulcers, patients seen at University College Hospital. in particular, are being reported with increasing frequency (Ellis, 1948; Konstam, 1959). The symp- AETIOLOGY Twelve (92.3 %) of the fistulas resulted toms and complications of duodenal ulcers in from chronic duodenal ulcer and in only one case Nigerians are the same as elsewhere, but the relative from gall bladder disease. incidence of these complications differs markedly. Pyloric stenosis is the commonest complication CLINICAL FEATURES There were no special symp- followed by haematemesis and malaena in that order toms or signs for this complication. All patients (Antia and Solanke, 1967; Solanke and Lewis, except the one with gall bladder disease presented 1968). Perforation though present is not very com- with symptoms of chronic duodenal ulcer or with mon. those of pyloric stenosis of which theie were four A remarkable complication found in some of our cases. In the case with gall bladder disease the history patients with duodenal ulcer who present them- was short and characterized by fever, right-sided selves for radiological examination is the formation abdominal pain, jaundice, and dark urine.
    [Show full text]
  • A Drug-Induced Cholestatic Pattern
    Review articles Hepatotoxicity: A Drug-Induced Cholestatic Pattern Laura Morales M.,1 Natalia Vélez L.,1 Octavio Germán Muñoz M., MD.2 1 Medical Student in the Faculty of Medicine and Abstract the Gastrohepatology Group at the Universidad de Antioquia in Medellín, Colombia Although drug induced liver disease is a rare condition, it explains 40% to 50% of all cases of acute liver 2 Internist and Hepatologist at the Hospital Pablo failure. In 20% to 40% of the cases, the pattern is cholestatic and is caused by inhibition of the transporters Tobon Uribe and in the Gastrohepatology Group at that regulate bile synthesis. This reduction in activity is directly or indirectly mediated by drugs and their me- the Universidad de Antioquia in Medellín, Colombia tabolites and/or by genetic polymorphisms and other risk factors of the patient. Its manifestations range from ......................................... biochemical alterations in the absence of symptoms to acute liver failure and chronic liver damage. Received: 30-01-15 Although there is no absolute test or marker for diagnosis of this disease, scales and algorithms have Accepted: 26-01-16 been developed to assess the likelihood of cholestatic drug induced liver disease. Other types of evidence are not routinely used because of their complexity and cost. Diagnosis is primarily based on exclusion using circumstantial evidence. Cholestatic drug induced liver disease has better overall survival rates than other patters, but there are higher risks of developing chronic liver disease. In most cases, the patient’s condition improves when the drug responsible for the damage is removed. Hemodialysis and transplantation should be considered only for selected cases.
    [Show full text]
  • Acute Liver Failure J G O’Grady
    148 Postgrad Med J: first published as 10.1136/pgmj.2004.026005 on 4 March 2005. Downloaded from REVIEW Acute liver failure J G O’Grady ............................................................................................................................... Postgrad Med J 2005;81:148–154. doi: 10.1136/pgmj.2004.026005 Acute liver failure is a complex multisystemic illness that account for most cases, but a significant number of patients have no definable cause and are evolves quickly after a catastrophic insult to the liver classified as seronegative or of being of indeter- leading to the development of encephalopathy. The minate aetiology. Paracetamol is the commonest underlying aetiology and the pace of progression strongly cause in the UK and USA.2 Idiosyncratic reac- tions comprise another important group. influence the clinical course. The commonest causes are paracetamol, idiosyncratic drug reactions, hepatitis B, and Viral seronegative hepatitis. The optimal care is multidisciplinary ALF is an uncommon complication of viral and up to half of the cases receive liver transplants, with hepatitis, occurring in 0.2%–4% of cases depend- ing on the underlying aetiology.3 The risk is survival rates around 75%–90%. Artificial liver support lowest with hepatitis A, but it increases with the devices remain unproven in efficacy in acute liver failure. age at time of exposure. Hepatitis B can be associated with ALF through a number of ........................................................................... scenarios (table 2). The commonest are de novo infection and spontaneous surges in viral repli- cation, while the incidence of the delta virus cute liver failure (ALF) is a complex infection seems to be decreasing rapidly. multisystemic illness that evolves after a Vaccination should reduce the incidence of Acatastrophic insult to the liver manifesting hepatitis A and B, while antiviral drugs should in the development of a coagulopathy and ameliorate replication of hepatitis B.
    [Show full text]
  • Imaging of Biliary Infections
    3 Imaging of Biliary Infections Onofrio Catalano, MD1 Ronald S. Arellano, MD2 1 Division of Abdominal Imaging, Department of Radiology, Address for correspondence Onofrio Catalano, MD, Division of Massachusetts General Hospital, Harvard Medical School, Abdominal Imaging, Department of Radiology, Massachusetts Boston, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, 2 Division of Interventional Radiology, Department of Radiology, Boston, MA 02114 (e-mail: [email protected]). Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts Dig Dis Interv 2017;1:3–7. Abstract Biliary tract infections cover a wide spectrum of etiologies and clinical presentations. Imaging plays an important role in understanding the etiology and as well as the extent Keywords of disease. Imaging also plays a vital role in assessing treatment response once a ► biliary infections diagnosis is established. This article will review the imaging findings of commonly ► cholangitides encountered biliary tract infectious diseases. ► parasites ► immunocompromised ► echinococcal Infections of the biliary tree can have a myriad of clinical and duodenum can lead toa cascade ofchanges tothehost immune imaging manifestations depending on the infectious etiolo- defense mechanisms of chemotaxis and phagocytosis.7 The gy, underlying immune status of the patient and extent of resultant lackof bile and secretory immunoglobulin A from the involvement.1,2 Bacterial infections account for the vast gastrointestinal tract lead
    [Show full text]
  • Management of Autoimmune Liver Diseases After Liver Transplantation
    Review Management of Autoimmune Liver Diseases after Liver Transplantation Romelia Barba Bernal 1,† , Esli Medina-Morales 1,† , Daniela Goyes 2 , Vilas Patwardhan 1 and Alan Bonder 1,* 1 Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA; [email protected] (R.B.B.); [email protected] (E.M.-M.); [email protected] (V.P.) 2 Department of Medicine, Loyola Medicine—MacNeal Hospital, Berwyn, IL 60402, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-617-632-1070 † These authors contributed equally to this project. Abstract: Autoimmune liver diseases are characterized by immune-mediated inflammation and even- tual destruction of the hepatocytes and the biliary epithelial cells. They can progress to irreversible liver damage requiring liver transplantation. The post-liver transplant goals of treatment include improving the recipient’s survival, preventing liver graft-failure, and decreasing the recurrence of the disease. The keystone in post-liver transplant management for autoimmune liver diseases relies on identifying which would be the most appropriate immunosuppressive maintenance therapy. The combination of a steroid and a calcineurin inhibitor is the current immunosuppressive regimen of choice for autoimmune hepatitis. A gradual withdrawal of glucocorticoids is also recommended. Citation: Barba Bernal, R.; On the other hand, ursodeoxycholic acid should be initiated soon after liver transplant to prevent Medina-Morales, E.; Goyes, D.; recurrence and improve graft and patient survival in primary biliary cholangitis recipients. Unlike the Patwardhan, V.; Bonder, A. Management of Autoimmune Liver previously mentioned autoimmune diseases, there are not immunosuppressive or disease-modifying Diseases after Liver Transplantation.
    [Show full text]
  • Spontaneous Bacterial Peritonitis: Recent Guidelines and Beyond R Wiest,1 a Krag,2 a Gerbes3
    Downloaded from gut.bmj.com on May 31, 2012 - Published by group.bmj.com Recent advances in clinical practice Spontaneous bacterial peritonitis: recent guidelines and beyond R Wiest,1 A Krag,2 A Gerbes3 1Department for visceral surgery INTRODUCTION prognosis in various cohorts of patients with SBP and medicine, University Spontaneous bacterial peritonitis (SBP) is the most are summarised in figure 1 and include age,16 20 Hospital Bern, Switzerland 18 20 23 16 18 2 frequent and life-threatening infection in patients Child score, intensive care, nosocomial Department of 18 24 25 Gastroenterology, Hvidovre with liver cirrhosis requiring prompt recognition origin, hepatic encephalopathy, elevated 26 University Hospital, and treatment. It is defined by the presence of >250 serum creatinine and bilirubin, lack of infection Copenhagen, Denmark polymorphonuclear cells (PMN)/mm3 in ascites in resolution/need to escalate treatment and culture 3 e Klinikum of the University of the absence of an intra-abdominal source of infec- positivity27 29 as well as the presence of bacter- Munich, Munich, Germany tion or malignancy. In this review we discuss the aemia30 and CARD15/NOD2 variants as a genetic fl 31 Correspondence to current opinions re ected by recent guidelines risk factor. It is important to stress in this context Professor Dr Reiner Wiest, (American Association for the Study of Liver that the only factors that are modifiable in this Department for visceral surgery Diseases, European Association for the Study of the scenario are timely diagnosis and effective first-line and medicine, University Liver, Deutsche Gesellschaft für Verdauungs- und treatment. Hospital Bern, 3010 Bern, 1e4 Switzerland; Stoffwechselkrankheiten), with particular focus [email protected] on controversial issues as well as open questions Bacterial translocation (BT) and pathophysiology that need to be addressed in the future.
    [Show full text]
  • Hepatitis A, B, and C: Learn the Differences
    Hepatitis A, B, and C: Learn the Differences Hepatitis A Hepatitis B Hepatitis C caused by the hepatitis A virus (HAV) caused by the hepatitis B virus (HBV) caused by the hepatitis C virus (HCV) HAV is found in the feces (poop) of people with hepa- HBV is found in blood and certain body fluids. The virus is spread HCV is found in blood and certain body fluids. The titis A and is usually spread by close personal contact when blood or body fluid from an infected person enters the body virus is spread when blood or body fluid from an HCV- (including sex or living in the same household). It of a person who is not immune. HBV is spread through having infected person enters another person’s body. HCV can also be spread by eating food or drinking water unprotected sex with an infected person, sharing needles or is spread through sharing needles or “works” when contaminated with HAV. “works” when shooting drugs, exposure to needlesticks or sharps shooting drugs, through exposure to needlesticks on the job, or from an infected mother to her baby during birth. or sharps on the job, or sometimes from an infected How is it spread? Exposure to infected blood in ANY situation can be a risk for mother to her baby during birth. It is possible to trans- transmission. mit HCV during sex, but it is not common. • People who wish to be protected from HAV infection • All infants, children, and teens ages 0 through 18 years There is no vaccine to prevent HCV.
    [Show full text]
  • Clinical Biliary Tract and Pancreatic Disease
    Clinical Upper Gastrointestinal Disorders in Urgent Care, Part 2: Biliary Tract and Pancreatic Disease Urgent message: Upper abdominal pain is a common presentation in urgent care practice. Narrowing the differential diagnosis is sometimes difficult. Understanding the pathophysiology of each disease is the key to making the correct diagnosis and providing the proper treatment. TRACEY Q. DAVIDOFF, MD art 1 of this series focused on disorders of the stom- Pach—gastritis and peptic ulcer disease—on the left side of the upper abdomen. This article focuses on the right side and center of the upper abdomen: biliary tract dis- ease and pancreatitis (Figure 1). Because these diseases are regularly encountered in the urgent care center, the urgent care provider must have a thorough understand- ing of them. Biliary Tract Disease The gallbladder’s main function is to concentrate bile by the absorption of water and sodium. Fasting retains and concentrates bile, and it is secreted into the duodenum by eating. Impaired gallbladder contraction is seen in pregnancy, obesity, rapid weight loss, diabetes mellitus, and patients receiving total parenteral nutrition (TPN). About 10% to 15% of residents of developed nations will form gallstones in their lifetime.1 In the United States, approximately 6% of men and 9% of women 2 have gallstones. Stones form when there is an imbal- ©Phototake.com ance in the chemical constituents of bile, resulting in precipitation of one or more of the components. It is unclear why this occurs in some patients and not others, Tracey Q. Davidoff, MD, is an urgent care physician at Accelcare Medical Urgent Care in Rochester, New York, is on the Board of Directors of the although risk factors do exist.
    [Show full text]
  • Diagnosis and Management of Primary Biliary Cholangitis Ticle
    REVIEW ArtICLE 1 see related editorial on page x Diagnosis and Management of Primary Biliary Cholangitis TICLE R Zobair M. Younossi, MD, MPH, FACG, AGAF, FAASLD1, David Bernstein, MD, FAASLD, FACG, AGAF, FACP2, Mitchell L. Shifman, MD3, Paul Kwo, MD4, W. Ray Kim, MD5, Kris V. Kowdley, MD6 and Ira M. Jacobson, MD7 Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune disease with a variable progressive course. PBC can cause debilitating symptoms including fatigue and pruritus and, if left untreated, is associated with a high risk of cirrhosis and related complications, liver failure, and death. Recent changes to the PBC landscape include a REVIEW A name change, updated guidelines for diagnosis and treatment as well as new treatment options that have recently become available. Practicing clinicians face many unanswered questions when managing PBC. To assist these healthcare providers in managing patients with PBC, the American College of Gastroenterology (ACG) Institute for Clinical Research & Education, in collaboration with the Chronic Liver Disease Foundation (CLDF), organized a panel of experts to evaluate and summarize the most current and relevant peer-reviewed literature regarding PBC. This, combined with the extensive experience and clinical expertise of this expert panel, led to the formation of this clinical guidance on the diagnosis and management of PBC. Am J Gastroenterol https://doi.org/10.1038/s41395-018-0390-3 INTRODUCTION addition, diagnosis and treatment guidelines are changing and a Primary biliary cholangitis (PBC) is a chronic, cholestatic, auto- number of guidelines have been updated [4, 5]. immune disease with a progressive course that may extend over Because of important changes in the PBC landscape, and a num- many decades.
    [Show full text]
  • Managing Liver Failure D a Kelly
    660 Postgrad Med J: first published as 10.1136/pmj.78.925.660 on 1 November 2002. Downloaded from BEST PRACTICE Managing liver failure D A Kelly ............................................................................................................................. Postgrad Med J 2002;78:660–667 Liver disease is rare in childhood, but important new Clinical presentation developments have altered the natural history and The clinical presentation depends on the aeti- ology of acute liver failure but the presentation outcome. It is important that clinicians are aware of may either be acute, within days, or prolonged to these diseases and their management. Acute liver failure 10 weeks if due to metabolic liver disease. The is most often due to viral hepatitis, paracetamol extent of jaundice and encephalopathy is variable in the early stages, but all children have coagu- overdose, or inherited metabolic liver disease. The lopathy. Encephalopathy is particularly difficult to clinical presentation includes jaundice, coagulopathy, diagnose in neonates. Vomiting and poor feeding and encephalopathy. Early diagnosis is necessary to are early signs, while irritability and reversal of day/night sleep patterns indicates more estab- prevent complications such as cerebral oedema, lished hepatic encephalopathy. In older children gastrointestinal bleeding, and renal failure. Early encephalopathy may present with aggressive supportive management, in particular intravenous behaviour or convulsions. N-acetylcysteine, may be effective but liver Neonatal acute liver failure transplantation is usually the definitive treatment and The commonest cause of acute liver failure in thus early referral to a specialist unit for liver neonates is septicaemia secondary to Escherichia coli, Staphylococcus aureus, or herpes simplex (box 1 transplantation is mandatory. Chronic liver failure may and table 1).
    [Show full text]
  • Acute Liver Failure
    Acute Liver Failure ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• When liver failure occurs in a previou ly healthy individual, it onset is often o rapid that it take experienced physicians by WILLIAM M. LEE surprise. Terms such a hyperacute or fulminant hepatic necrosis have been u ed to emphasize the rapidity and everity of the JULIE POLSON condition. The onset of acute liver failure is heralded by an altered mental state, often with agitation and confusion that may proceed to coma, and by evidence of coagulopathy [1 - 4]. The diagno is of acute liver failure require that these symptom develop in a patient without preexisting chronic liver disease. Although not all observers agree on precise definitions, it is generally accepted that onset of liver-related illness (usually, but not always, accompanied by jaundice) les than 8 weeks before patient presentation with altered mentation and coagulopathy fits the designation of acute liver failure. Development of these signs within a week of onset of liver disease and as much as 6 months from the first sign of illness is sometimes referred to as hyperacute and ubacute liver failure, respectively. An immediate challenge in managing sud1 patients is deter­ mination of the cause of acute liver failure in each case. Wherea certain factors, such a extent of encephalopathy and development of various complications, have an impact on outcome, the underlying etiology best determines the likeli­ hood of spontaneous survival or the need for urgent liver trans­ plantation [3,4]. The primary cause of acute liver failure vary in prevalence in different region of the world, and include drug toxicity and viral infections; there i also a large category of cases in which the pecific etiology cannot be determined.
    [Show full text]